ArticleFuture healthcare journal2021
Making trials part of good clinical care: lessons from the RECOVERY trial.
Article in Future healthcare journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.The Lancet. Infectious diseases · 2026Trial
- The patient-centric development of an inclusive multi-arm multi-stage trial for Parkinson's disease.Brain communications · 2026Article
- Rising to the challenges of research in multiple long-term conditions: health and social care research ecosystem approaches.BMJ open · 2025Review
- Master Protocol Design With Hybrid Control for Efficient Early-Phase Trial Consolidation.JCO precision oncology · 2025Article
- Agreement and utility of coded primary and secondary care data for long-term follow-up of clinical trial outcomes.BMC medical research methodology · 2025Article
- How to build a better clinical trial ecosystem for future infectious disease emergencies in Japan: Findings from a narrative review and stakeholder meetings.Global health & medicine · 2025Review
- Large simple randomized controlled trials-from drugs to medical devices: lessons from recent experience.Trials · 2025Review
- Unlocking New Potential: Drug Repurposing and Innovative Pharmaceutics.Current drug research reviews · 2025Article
- Article
- Framework of the strengths and challenges of clinically integrated trials: An expert panel report.American heart journal · 2024Review
- Article
- Associate Principal Investigators and the HEAL-COVID trial: good for trainees, good for trials.Trials · 2024Article
- ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic.Journal of clinical and translational science · 2024Review
- Embedding clinical trial elements into clinical practice: Experiences from trial designers and implementers.Journal of clinical and translational science · 2024Article
- Designing and Implementing "Living and Breathing" Clinical Trials: An Overview and Lessons Learned from the COVID-19 Pandemic.Critical care clinics · 2023Review
- Delivering trials in the NHS: more than worth it.Clinical medicine (London, England) · 2023Article
- Identification of the ideal recruitment situation in pandemic research: learning from the RECOVERY trial in Northern England: a qualitative study.BMJ leader · 2023Article
- Adaptive, platform trials assessing therapies for hospitalized COVID-19 patients: Informed consent forms omitted a few important elements of information.Journal of global health · 2023Article
- Article
- If Providing Best Care Means Being at the Cutting Edge of Research, Should It Be Implemented System-wide? Comment on "'We're Not Providing the Best Care If We Are Not on the Cutting Edge of Research': A Research Impact Evaluation at a Regional Australian Hospital and Health Service".International journal of health policy and management · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
When COVID-19 hit the UK in early 2020, there were no known treatments for a condition that results in the death of around one in four patients hospitalised with this disease. Around the world, possible treatments were administered to huge numbers of patients, without any reliable assessments of safety and efficacy. The rapid generation of high-quality evidence was vital. RECOVERY is a streamlined, pragmatic, randomised controlled trial, which was set up in response to this challenge. As of April 2021, over 39,000 patients have been enrolled from 178 hospital sites in the UK. Within 100 days of its initiation, RECOVERY demonstrated that dexamethasone improves survival for patients with severe disease; a result that was rapidly implemented in the UK and internationally saving hundreds of thousands of lives. Importantly, it also showed that other widely used treatments (such as hydroxychloroquine and azithromycin) have no meaningful benefit for hospitalised patients. This was only possible through randomisation of large numbers of patients and the adoption of streamlined and pragmatic procedures focused on quality, together with widespread collaboration focused on a single goal. RECOVERY illustrates how clinical trials and healthcare can be integrated, even in a pandemic. This approach provides new opportunities to generate the evidence needed for high-quality healthcare not only for a pandemic but for the many other conditions that place a burden on patients and the healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.